tenofovir

Abacavir or tenofovir for first-line?

Graham Stocks — Wed, 23 Nov 2011 21:10:02 -0800

According to the Canadian Observational CohortIn epidemiology, a group of individuals with some characteristics in common. A cohort study is a special kind of clinical trial which looks at a treatment or treatment strategy in a cohort of people. collaboration, abacavir (ABC) or tenofovir (TDF) are equally effective in first-line treatment.

The authors found that in their group of treatment-naive patients starting treatment, there was no difference in time to suppression with ABC/3TC (Kivexa) versus TDF/FTC (Truvada).

Tenofovir vs abacavir: the saga continues

Graham Stocks — Wed, 31 Aug 2011 23:16:26 -0700

Compared to abacavir, tenofovir does increase bone mineral density (BMD) loss but not fracture risk, according to the results from the STEAL trial reported at the IAS Conference in Rome.

Tenofovir may reduce inflammation

Graham Stocks — Wed, 25 May 2011 23:12:22 -0700

It appears that the antiretroviralA medication or other substance which is active against retroviruses such as HIV. NRTIA type of anti-HIV drug that works by inhibiting a stage of the HIV life cycle called reverse transcription. Non-nucleosides work in a similar way, but are chemically different. tenofovir (found in Viread, Truvada and Atripla) may also have a calming effect on the immune system and provide protection against infections other than HIV. Laboratory tests have found that tenofovir offered two types of protection. First, it suppressed the production of inflammatory messengers, such as Interleukin-8 (IL-8).

Snippets from ASHM

Graham Stocks — Wed, 01 Dec 2010 17:34:41 -0800

The Australasian HIV/AIDS Conference was held in Sydney in October. Here are some of the treatment highlights:

AIDS 2010: microbicide breakthrough

Paul Kidd — Wed, 21 Jul 2010 00:42:16 -0700

In what is being called a major breakthrough, a trial of a vaginal microbicide gel in South African women has shown for the first time that such a product can be effective against HIV infection.

Antiretrovirals and your kidneys

Graham Stocks — Wed, 25 Nov 2009 21:52:21 -0800

Despite having been linked to the kidneys, tenofovir (Viread and also in the combination pill Truvada) appears not to cause more problems than other NRTIA type of anti-HIV drug that works by inhibiting a stage of the HIV life cycle called reverse transcription. Non-nucleosides work in a similar way, but are chemically different. drugs, US investigators have reported.

Bone health and HIV

Jill Sergeant — Thu, 04 Jun 2009 23:13:43 -0700

Those of us with HIV are more likely to have conditions such as osteopenia (low bone mineral density) and osteoporosis (weakened bones) than our negative contemporaries.

FTC approved, ddC to be withdrawn

Paul Kidd — Wed, 18 May 2005 07:07:19 -0700

A new antiretroviralA medication or other substance which is active against retroviruses such as HIV. medication, FTC (emtricitabine, Emtriva) was listed on the PBS[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. and became available for S100 prescription from 1 April.

Cambodian PREP trial halted

Paul Kidd — Sat, 14 Aug 2004 15:00:38 -0700

A controversial Cambodian trial of tenofovir for pre-exposure prophylaxis (PREP) is unlikely to proceed after sex workers and the Cambodian government claimed the trial did not include adequate safeguards for the health and human rights of the participants.

Pre-exposure prophylaxis study for Cambodia

Sun, 14 Dec 2003 14:00:36 -0800

Australian researchers have teamed up with the US and Cambodia to conduct a study of the potential of the HIV antiviralA medication or substance which is active against one or more viruses. May include anti-HIV drugs, but these are more accurately termed antiretrovirals. tenofovir, taken daily, to prevent HIV infection in women at high risk.